Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00067457
Other study ID # S3B30048
Secondary ID
Status Completed
Phase Phase 3
First received August 20, 2003
Last updated April 15, 2015
Start date June 2003
Est. completion date December 2005

Study information

Verified date April 2015
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the safety and effectiveness of as needed versus fixed dosing of an investigational medication for women with severe diarrhea-predominant Irritable Bowel Syndrome (IBS) who have failed conventional therapy.


Recruitment information / eligibility

Status Completed
Enrollment 700
Est. completion date December 2005
Est. primary completion date December 2005
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Diagnosed with severe diarrhea-predominant Irritable Bowel Syndrome (IBS).

- Failed conventional therapy.

- Willing to make daily calls on a touch-tone telephone.

Exclusion criteria:

- History of or current chronic or severe constipation.

- Bloody diarrhea, abdominal pain with rectal bleeding.

- Thrombophlebitis.

- Abnormal thyroid stimulating hormone (TSH) value.

- Alcohol and/or substance abuse within past two years.

- Pregnant or lactating.

- History/treatment of malignancy within past five years.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Intervention

Drug:
alosetron


Locations

Country Name City State
Australia GSK Investigational Site Nedlands Western Australia
United States GSK Investigational Site Albany New York
United States GSK Investigational Site Albuquerque New Mexico
United States GSK Investigational Site Anderson South Carolina
United States GSK Investigational Site Annapolis Maryland
United States GSK Investigational Site Atlanta Georgia
United States GSK Investigational Site Atlanta Georgia
United States GSK Investigational Site Austin Texas
United States GSK Investigational Site Baltimore Maryland
United States GSK Investigational Site Baltimore Maryland
United States GSK Investigational Site Bellbrook Ohio
United States GSK Investigational Site Belleair Bluffs Florida
United States GSK Investigational Site Bellevue Washington
United States GSK Investigational Site Bensalem Pennsylvania
United States GSK Investigational Site Berlin New Jersey
United States GSK Investigational Site Beverly Hills California
United States GSK Investigational Site Binghamton New York
United States GSK Investigational Site Birmingham Alabama
United States GSK Investigational Site Birmingham Alabama
United States GSK Investigational Site Blackwood New Jersey
United States GSK Investigational Site Blue Ridge Georgia
United States GSK Investigational Site Boca Raton Florida
United States GSK Investigational Site Boise Idaho
United States GSK Investigational Site Bradenton Florida
United States GSK Investigational Site Bristol Connecticut
United States GSK Investigational Site Bristol Tennessee
United States GSK Investigational Site Brooklyn Center Minnesota
United States GSK Investigational Site Burlington Massachusetts
United States GSK Investigational Site Carlsbad California
United States GSK Investigational Site Cary North Carolina
United States GSK Investigational Site Cedar Knolls New Jersey
United States GSK Investigational Site Centennial Colorado
United States GSK Investigational Site Charleston South Carolina
United States GSK Investigational Site Charlotte North Carolina
United States GSK Investigational Site Chesapeake Virginia
United States GSK Investigational Site Chesterfield Missouri
United States GSK Investigational Site Chicago Illinois
United States GSK Investigational Site Chicago Illinois
United States GSK Investigational Site Christiansburg Virginia
United States GSK Investigational Site Cincinnati Ohio
United States GSK Investigational Site Clarksville Tennessee
United States GSK Investigational Site Clearwater Florida
United States GSK Investigational Site Clearwater Florida
United States GSK Investigational Site Clive Iowa
United States GSK Investigational Site Coeur D'Alene Idaho
United States GSK Investigational Site Colorado Springs Colorado
United States GSK Investigational Site Columbus Ohio
United States GSK Investigational Site Columbus Ohio
United States GSK Investigational Site Concord California
United States GSK Investigational Site Conroe Texas
United States GSK Investigational Site Covington Louisiana
United States GSK Investigational Site Dallas Texas
United States GSK Investigational Site Danville Virginia
United States GSK Investigational Site Deland Florida
United States GSK Investigational Site Duncansville Pennsylvania
United States GSK Investigational Site Dunwoody Georgia
United States GSK Investigational Site Encinitas California
United States GSK Investigational Site Endwell New York
United States GSK Investigational Site Farmington Hills Michigan
United States GSK Investigational Site Fayetteville Georgia
United States GSK Investigational Site Feasterville Pennsylvania
United States GSK Investigational Site Florence Kentucky
United States GSK Investigational Site Fresno California
United States GSK Investigational Site Gainesville Florida
United States GSK Investigational Site Garden Grove California
United States GSK Investigational Site Gastonia North Carolina
United States GSK Investigational Site Gig Harbor Washington
United States GSK Investigational Site Great Neck New York
United States GSK Investigational Site Greensboro North Carolina
United States GSK Investigational Site Greenville North Carolina
United States GSK Investigational Site Haysville Kansas
United States GSK Investigational Site Hollywood Florida
United States GSK Investigational Site Houston Texas
United States GSK Investigational Site Humble Texas
United States GSK Investigational Site Huntsville Alabama
United States GSK Investigational Site Indianapolis Indiana
United States GSK Investigational Site Indianapolis Indiana
United States GSK Investigational Site Jackson Tennessee
United States GSK Investigational Site Jacksonville North Carolina
United States GSK Investigational Site Jacksonville Florida
United States GSK Investigational Site Jacksonville Florida
United States GSK Investigational Site Jeffersonville Indiana
United States GSK Investigational Site Johnson City Tennessee
United States GSK Investigational Site Kansas City Kansas
United States GSK Investigational Site Kingsport Tennessee
United States GSK Investigational Site Kissimmee Florida
United States GSK Investigational Site Knoxville Tennessee
United States GSK Investigational Site La Crosse Wisconsin
United States GSK Investigational Site Lacey Washington
United States GSK Investigational Site Lafayette Louisiana
United States GSK Investigational Site Lanham Maryland
United States GSK Investigational Site Las Vegas Nevada
United States GSK Investigational Site Levittown Pennsylvania
United States GSK Investigational Site Lexington Kentucky
United States GSK Investigational Site Lexington Kentucky
United States GSK Investigational Site Libertyville Illinois
United States GSK Investigational Site Lincoln Nebraska
United States GSK Investigational Site Little Rock Arkansas
United States GSK Investigational Site Littleton Colorado
United States GSK Investigational Site Longmont Colorado
United States GSK Investigational Site Los Angeles California
United States GSK Investigational Site Madison Wisconsin
United States GSK Investigational Site Madisonville Kentucky
United States GSK Investigational Site Media Pennsylvania
United States GSK Investigational Site Melbourne Florida
United States GSK Investigational Site Memphis Tennessee
United States GSK Investigational Site Meridian Idaho
United States GSK Investigational Site Mobile Alabama
United States GSK Investigational Site Moline Illinois
United States GSK Investigational Site Monroe Louisiana
United States GSK Investigational Site Morrisville Pennsylvania
United States GSK Investigational Site Morton Grove Illinois
United States GSK Investigational Site Nashville Tennessee
United States GSK Investigational Site New Orleans Louisiana
United States GSK Investigational Site New Orleans Louisiana
United States GSK Investigational Site Norfolk Virginia
United States GSK Investigational Site Norfolk Virginia
United States GSK Investigational Site North Little Rock Arkansas
United States GSK Investigational Site North Miami Beach Florida
United States GSK Investigational Site North Richland Hills Texas
United States GSK Investigational Site Northville Michigan
United States GSK Investigational Site Oakbrook Terrace Illinois
United States GSK Investigational Site Oakhurst New Jersey
United States GSK Investigational Site Oklahoma City Oklahoma
United States GSK Investigational Site Omaha Nebraska
United States GSK Investigational Site Orange California
United States GSK Investigational Site Oxon Hill Maryland
United States GSK Investigational Site Pasadena Texas
United States GSK Investigational Site Passaic New Jersey
United States GSK Investigational Site Pell City Alabama
United States GSK Investigational Site Penndel Pennsylvania
United States GSK Investigational Site Peoria Illinois
United States GSK Investigational Site Petoskey Michigan
United States GSK Investigational Site Philadelphia Pennsylvania
United States GSK Investigational Site Philadelphia Pennsylvania
United States GSK Investigational Site Philadelphia Pennsylvania
United States GSK Investigational Site Pittsburgh Pennsylvania
United States GSK Investigational Site Pittsford New York
United States GSK Investigational Site Pomona New York
United States GSK Investigational Site Portland Oregon
United States GSK Investigational Site Portland Oregon
United States GSK Investigational Site Raleigh North Carolina
United States GSK Investigational Site Reading Pennsylvania
United States GSK Investigational Site Richmond Virginia
United States GSK Investigational Site Rockford Illinois
United States GSK Investigational Site Rome Georgia
United States GSK Investigational Site Roseville California
United States GSK Investigational Site Saginaw Michigan
United States GSK Investigational Site Salt Lake City Utah
United States GSK Investigational Site San Antonio Texas
United States GSK Investigational Site San Antonio Texas
United States GSK Investigational Site San Diego California
United States GSK Investigational Site San Diego California
United States GSK Investigational Site San Diego California
United States GSK Investigational Site San Francisco California
United States GSK Investigational Site San Francisco California
United States GSK Investigational Site San Francisco California
United States GSK Investigational Site Santa Ana California
United States GSK Investigational Site Savannah Georgia
United States GSK Investigational Site Sellersville Pennsylvania
United States GSK Investigational Site Severna Park Maryland
United States GSK Investigational Site Shreveport Louisiana
United States GSK Investigational Site Silver Spring Maryland
United States GSK Investigational Site Sioux Falls South Dakota
United States GSK Investigational Site South Bound Brook New Jersey
United States GSK Investigational Site Spring Hill Florida
United States GSK Investigational Site Spring Valley California
United States GSK Investigational Site St. Louis Missouri
United States GSK Investigational Site Stoneboro Pennsylvania
United States GSK Investigational Site Stuart Florida
United States GSK Investigational Site Sugar Land Texas
United States GSK Investigational Site Summerville South Carolina
United States GSK Investigational Site Tacoma Washington
United States GSK Investigational Site Tallassee Alabama
United States GSK Investigational Site Torrance California
United States GSK Investigational Site Towson Maryland
United States GSK Investigational Site Towson Maryland
United States GSK Investigational Site Tucson Arizona
United States GSK Investigational Site Tulsa Oklahoma
United States GSK Investigational Site Van Nuys California
United States GSK Investigational Site Virginia Beach Virginia
United States GSK Investigational Site Wandsworth Ohio
United States GSK Investigational Site Weber City Virginia
United States GSK Investigational Site Wheaton Maryland
United States GSK Investigational Site Wichita Kansas
United States GSK Investigational Site Willingboro New Jersey
United States GSK Investigational Site Wilmington North Carolina
United States GSK Investigational Site Wilmington North Carolina
United States GSK Investigational Site Winston-Salem North Carolina
United States GSK Investigational Site Woodlands Texas
United States GSK Investigational Site Zephyrhills Florida

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Subject self assessment of improvement between treatment groups using the IBS Global Improvement Scale; comparison of safety and tolerability between treatment groups with respect to adverse events & laboratory abnormalities. 12 Weeks
Secondary Comparison of treatment groups with respect to subject relief of IBS pain & discomfort; lower GI symptoms, changes in quality of life, lost workplace productivity, & lost household/leisure activity, & subject satisfaction with assigned study drug. 12 Weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05795049 - Genetic Carbohydrate Maldigestion as a Model to Study Food Hypersensitivity
Completed NCT02875847 - Effects of HMOs on Faecal Microbiota, Gastrointestinal Symptoms, Mucosal Immunity and Barrier Function in IBS Patients Phase 2
Withdrawn NCT02841878 - Genetic Determinism of Epithelial Barrier Defects in Irritable Bowel Syndrome N/A
Completed NCT02842281 - Microbiome Fructan Metabolism and Symptoms in Childhood IBS N/A
Completed NCT02092402 - Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome N/A
Completed NCT03964103 - qQ-lab Daily-IBS for Irritable Bowel Syndrome N/A
Completed NCT00401479 - A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers Phase 1
Completed NCT00421707 - Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome Phase 2
Not yet recruiting NCT06139744 - Efficacy and Safety of Dietary Supplementation of Diamine Oxidase to Improve Symptoms in Patients With IBS Phase 4
Recruiting NCT04506593 - Indiana University Gastrointestinal Motility Diagnosis Registry
Completed NCT01908465 - Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial Phase 4
Completed NCT01787253 - Microbe-Gut Interaction in Microscopic Colitis and Post-Infectious Irritable Bowel Syndrome (IBS)
Completed NCT00376896 - Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers Phase 1
Completed NCT00904696 - Tolerability and Effectiveness of Progut in Treatment of Irritable Bowel Syndrome N/A
Recruiting NCT05453084 - Exercise and Irritable Bowel Syndrome (IBS) N/A
Completed NCT03550742 - Effect of HMOs as Nutritional Support for Normal Bowel Movements in IBS Patients N/A
Terminated NCT01887002 - Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Phase 2
Completed NCT01774695 - Physical Activity in IBS - a Long Term Follow up N/A
Completed NCT01204515 - Abdominal Symptom Phenotype Study in Children N/A
Completed NCT00067561 - Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy Phase 3